HIV A6 Genome In ART Unsuccessful Patients On DOR (HIV-A6-DOR)

N

National Research Center for Epidemiology and Microbiology

Status

Not yet enrolling

Conditions

Virus-HIV

Treatments

Drug: Doravirine

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT05322083
MISP#60102

Details and patient eligibility

About

The aim of the study is to evaluate the efficacy of Doravirine (DOR) in the second-line therapy for patients infected with HIV-1 sub-subtype A6 and its derivatives and having the mutations to previously used drugs

Full description

During the study 60-80 HIV-infected patients in 2-4 investigation sites (AIDS Centers) across Russia with proven virological failure on first-line antiretroviral therapy (ART) including efavirenz (EFV) and nevirapine (NVP) will be enrolled. The blood samples, epidemiological, clinical and demographic data of patients participating in the study must be collected. All participants must provide written informed consent before the start of the study. Virological failure on NNRTI regimen in all the participants will be confirmed by HIV genotyping. All the patients with confirmed NNRTI mutations will be switched to DOR instead of EFV/NVP in the second-line therapy and enrolled to the study. The primary efficacy endpoints of ART with DOR will be weeks 8 and 24 (viral load + T-cell count). For all samples with virological failure at weeks 8 or 24 HIV-1 DNA sequences (full protease (PR) and partial reverse transcriptase (RT) regions) will be obtained using the in-house test system or commercial kit (Central Research Institute of Epidemiology, Moscow, Russia). In case of virological failure of DOR treatment, the analysis of drug resistance mutations will be carried out.

Enrollment

60 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • HIV-infection confirmed
  • > 18 years
  • Informed consent signed

Exclusion criteria

  • Pregnant women

Trial design

60 participants in 1 patient group

HIV patients
Description:
All patients will be prescribed treatment drugs in accordance with the national protocol by the doctors of the AIDS centers. The decision to prescribe Doravirine will also be made by doctors.
Treatment:
Drug: Doravirine

Trial contacts and locations

0

Loading...

Central trial contact

Anna Kuznetsova, PhD; Marina Bobkova, DrSci

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems